Michael S. Cookson, MD, MMHC, FACS

"We anticipate that in the next decade, breakthroughs in genetic profiling of tumors for precision therapies will further reduce suffering and death from bladder cancer," writes Michael S. Cookson, MD, MMHC.

"AI has...been increasingly utilized in the field of medicine, including cancer research, because of its potential to improve diagnostic accuracy, prognosis prediction, and personalized treatment planning," writes Michael S. Cookson, MD, MMHC.

"We are...entering a new era for patients with urologic malignancies. Furthermore, we are expanding our reach and influence in patient care designed to improve outcomes," writes Michael S. Cookson, MD, MMHC.

"Cancer doesn’t take a holiday or vacation, and it doesn’t care about a pandemic. Our efforts to reduce deaths from prostate cancer through screening and early detection must continue," writes Michael S. Cookson, MD, MMHC.

"What we still need to trial is the use of treatment intensification or triple therapy in men with high-risk localized and/or locally advanced disease," writes Michael S. Cookson, MD, MMHC.

"As we celebrate 50 years of successes, the Gleason grading system deserves recognition," writes Michael S. Cookson, MD, MMHC.

"The future is bright for immunotherapy in bladder cancer," writes Michael S. Cookson, MD, MMHC.

"As we celebrate the tremendous victories against cancer and commemorate 5 decades of progress, we are also reminded of the harsh reality that we have a war still to be won," writes Michael S. Cookson, MD, MMHC, co–editor in chief of Urology Times.

"The Will Rogers phenomenon continues to be impactful, and when combined with a precision treatment, the outcomes of this disease state will be “doubly improved” for generations to come," writes Michael S. Cookson, MD, MMHC.

"After a long period of stagnation and inertia, the bladder cancer space is alive and full of innovation and activation," writes Michael S. Cookson, MD, MMHC.